Roche: FDA approves generic version of cancer drug rituximab
(CercleFinance.com) - US health regulators have approved a generic version of Roche's cancer drug rituximab, a decision that follows the approval of many other biosimilars in the US over recent years.
The US Food and Drug Administration has approved Celltrion' Truxima as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with non-Hodgkin's lymphoma.
Truxima is the first biosimilar to be approved in the US for the treatment of non-Hodgkin's lymphoma, the FDA said.
Rituxan - which is manufactured by Roche unit Genentech - was originally approved in November 1997.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The US Food and Drug Administration has approved Celltrion' Truxima as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with non-Hodgkin's lymphoma.
Truxima is the first biosimilar to be approved in the US for the treatment of non-Hodgkin's lymphoma, the FDA said.
Rituxan - which is manufactured by Roche unit Genentech - was originally approved in November 1997.
Copyright (c) 2018 CercleFinance.com. All rights reserved.